Severe human infection with a novel avian-origin influenza A(H7N4) virus
Xiang Huo(Jiangsu Provincial Center for Disease Control and Prevention), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), George F. Gao(Chinese Center For Disease Control and Prevention), Fengming Wang, Feifei Hu(Shanghai University of Traditional Chinese Medicine), Haodi Huang(Jiangsu Provincial Center for Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Weirong Kong, Changjun Bao(Jiangsu Provincial Center for Disease Control and Prevention), Xiang Zhao(Chinese Academy of Sciences), Chao Li(Zhuhai People's Hospital), Cong Chen(Fujian University of Traditional Chinese Medicine), Xian Qi(Peking University), Dayan Wang(Sun Yat-sen University), Ying Chi(China Three Gorges University), Minghao Zhou(Jiangsu Provincial Center for Disease Control and Prevention), Ruiqi Ren(Chinese Center For Disease Control and Prevention), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Yiyue Ge(Jiangsu Provincial Center for Disease Control and Prevention), William J. Liu(Wenzhou Medical University), Daxin Ni(Chinese Center For Disease Control and Prevention)
Cited by 36
Related Papers
Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
|Trends in Microbiology|2016|3.1k
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.3k
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Viral targets for vaccines against COVID-19
|Nature reviews. Immunology|2020|1.1k